Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply
Aliment Pharmacol Ther
.
2020 Jun;51(11):1209-1210.
doi: 10.1111/apt.15735.
Authors
William J Sandborn
1
,
Julian Panés
2
,
Bruce E Sands
3
,
Walter Reinisch
4
,
Chinyu Su
5
,
Nervin Lawendy
5
,
Nana Koram
6
,
Haiyun Fan
5
,
Thomas V Jones
5
,
Irene Modesto
6
,
Daniel Quirk
5
,
Silvio Danese
7
Affiliations
1
Division of Gastroenterology, University of California, San Diego, La Jolla, CA, USA.
2
Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
3
Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
4
Medical University of Vienna, Vienna, Austria.
5
Pfizer Inc, Collegeville, PA, USA.
6
Pfizer Inc, New York, NY, USA.
7
Division of Gastroenterology, IBD Center, Humanitas University, Rozzano, Milan, Italy.
PMID:
32424928
DOI:
10.1111/apt.15735
No abstract available
Publication types
Letter
Comment
MeSH terms
Colitis, Ulcerative*
Humans
Piperidines
Pyrimidines
Pyrroles
Substances
Piperidines
Pyrimidines
Pyrroles
tofacitinib